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Early detection of acute renal failure by serum cystatin C.
Background. Acute renal failure (ARF) is associated with
high mortality. Presently, no specific therapy for ARF exists.
Therefore, early detection of ARF is critical to prevent its pro-
gression. However, serum creatinine, the standard marker to
detect ARF, demonstrates major limitations. We prospectively
evaluated whether serum cystatin C detected ARF earlier than
serum creatinine.
Methods. In 85 patients at high risk to develop ARF, serum
creatinine and cystatin C were determined daily. ARF was de-
fined according to the Risk of renal dysfunction, Injury to the
kidney, Failure of kidney function, Loss of kidney function,
and ESRD (RIFLE) classification when creatinine increased
by ≥50% (R-criteria), by ≥100% (I-criteria), or by ≥200%
(F-criteria). In analogy, ARF was detected when cystatin C in-
creased by ≥50%, by ≥100%, or by ≥200%.
Results. Forty-four patients developed ARF and 41 served
as controls. In ARF by R-, I-, and F-criteria, the increase of
cystatin C significantly preceded that of creatinine. Specifically,
serum cystatin C increased already by ≥50% 1.5 ± 0.6 days ear-
lier compared to creatinine. Serum cystatin C demonstrated a
high diagnostic value to detect ARF as indicated by area under
the curve of the ROC analysis of 0.82 and 0.97 on the two days
before the R-criteria was fulfilled by creatinine. Cystatin C de-
tected ARF according to the R-criteria with a sensitivity of 55%
and 82% on these days, respectively. Cystatin C also performed
excellently, detecting ARF defined by the I- and F-criteria two
days prior to creatinine, and moderately well predicting renal
replacement therapy in the further course of ARF. Addition-
ally, low T3- or T3/T4 syndrome, glucocorticoid deficiency and
excess did not affect cystatin C levels, adding to its usefulness
in critically ill patients with ARF.
Conclusion. Serum cystatin C is a useful detection marker
of ARF, and may detect ARF one to two days earlier than
creatinine.
Acute renal failure (ARF) is common in hospitalized
patients, with a mortality rate between 30% and 90% [1–
6]. ARF markedly increases the mortality rate indepen-
dently of other factors [3, 5, 7]. In the absence of effec-
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tive, specific therapies for ARF, the early and accurate
detection of ARF is crucial to prevent its progression,
and thereby, to potentially improve its outcome [8–10].
In clinical practice, the detection of ARF, which is charac-
terized by a rapid decline of the glomerular filtration rate
(GFR), is based on an increase of serum creatinine [11].
However, there are major limitations to the use of cre-
atinine for estimating glomerular filtration rate (GFR).
Serum creatinine does not accurately reflect GFR dur-
ing the nonsteady state of ARF by underestimating GFR
[12]. Thus, minor changes of creatinine, as typically seen
early in ARF, may already reflect substantial declines in
GFR. Furthermore, serum creatinine inaccurately esti-
mates GFR due to tubular secretion and reabsorption of
creatinine, and nonrenal factors that may apply to ARF
patients who are predominantly critically ill [12].
To overcome these obstacles, there is an extensive
search for improved laboratory markers of impaired re-
nal function [13, 14]. Cross-sectional studies in chronic
renal insufficiency identified serum cystatin C as a promis-
ing, easily measurable marker to estimate GFR with a
higher diagnostic value than serum creatinine [15, 16].
Cystatin C is a 13 kD endogenous cysteine proteinase in-
hibitor and is produced by nucleated cells at a constant
rate. Cystatin C is freely filtered by the glomerulus, re-
absorbed, and catabolized, but it is not secreted by the
tubules [17, 18]. Further studies demonstrated the supe-
riority of serum cystatin C compared to creatinine, espe-
cially to detect minor GFR reduction [19, 20]. This finding
was confirmed by a recent meta-analysis [21]. Previous
longitudinal studies on serum cystatin C predominantly
suggested that serum cystatin C performed better than
serum creatinine as a marker to detect acute changes of
GFR [22–26]. However, these studies were limited be-
cause they examined either GFR changes in small patient
samples or did not include controls [22, 23, 25, 26]. Fur-
thermore limiting, most studies were conducted in renal
transplant recipients early after transplantation [22–25],
and high-dose glucocorticoid medication may have inter-
fered with serum cystatin C [27, 28].
The purpose of this study was to prospectively evaluate
serum cystatin C as a marker to detect ARF and to test
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whether cystatin C could detect ARF earlier than serum
creatinine. In addition, we studied the effect of low T3- or
T3/T4 syndrome, glucocorticoid deficiency, and excess on
serum cystatin C, because these conditions are frequent in
critical illness, such as ARF, and may limit the diagnostic
value of cystatin C.
METHODS
All patients in three surgical and medical intensive
care units (ICU) at the University Hospital Essen with
initially normal GFR, defined by a serum creatinine be-
low 115 lmol/L measured at least twice consecutively,
were screened for predisposing factors of ARF. Predis-
posing factors screened for were age above 70 years,
cardiogenic or hemorrhagic shock, decompensated liver
cirrhosis, chronic heart failure NYHA class IV, malignant
lymphoma or acute leukemia, acute respiratory failure
requiring mechanical ventilation, diabetes, valve surgery
with aortocoronary bypass, and sepsis [29–31]. Patients
with two or more predisposing factors were regarded as
high-risk patients for ARF and were further evaluated.
We excluded patients with aortic aneurysms, with hyper-
or hypothyroidism, and patients receiving glucocorticoid
or thyroid hormone therapy, because these conditions
were demonstrated to be associated with increased or
decreased serum cystatin C levels independent of renal
function [27, 28, 32–34]. We also excluded patients ex-
pected to be possibly discharged from ICU within the
next four days or to decease shortly, and those on re-
nal replacement therapy within four days. No patient
received cimetidine or trimethoprim. Eighty-five high-
risk patients for ARF were included and prospectively
studied.
From each patient serum samples were collected daily
between 7 and 9 a.m. until discharge from ICU. Serum
creatinine was determined on the day of sample collec-
tion and aliquots for serum cystatin C, total triidothy-
ronine (T3), total thyroxine (T4), free thyroxine (fT4),
thyroid stimulating hormone (TSH), and cortisol mea-
surements were stored at −20◦C. Serum creatinine was
measured by a modified Jaffe method with protein pre-
cipitation using an alkaline picrate reaction. Serum cys-
tatin C was measured by immunonephelometric method
(Dade Behring, Marburg, Germany) within two weeks
after sample collection. Upper reference values were
114 lmol/L for serum creatinine and 1.01 mg/L for serum
cystatin C, as previously described [16]. Previously, in our
laboratory intra-assay and interassay imprecision aver-
aged 3.0% and 4.4%, respectively. Accuracy, expressed
as the difference between the expected and the mea-
sured values of cystatin C control material, was 2.8%.
Clinical data were extracted from records of the hospi-
tal stay. ARF was detected according to the first three
RIFLE (indicating the level of renal impairment: Risk
of renal dysfunction, Injury to the kidney, Failure of kid-
ney function, Loss of kidney function, and ESRD) cri-
teria of the GFR domain [35], which are (1) risk (R):
an increase of serum creatinine ≥50% from baseline; (2)
injury (I): an increase of serum creatinine ≥100% from
baseline; and (3) failure (F): an increase of serum cre-
atinine ≥200% from baseline. In analogy, ARF was de-
tected when cystatin C increased by ≥50%, ≥100%, or
≥200% from baseline. In patients with ARF, serum crea-
tinine and cystatin C were analyzed for the day the ARF
risk criteria was fulfilled according to serum creatinine
(R-day 0), and on the three days prior to R-day 0 (R-day
−3 to −1). R-day –3 was termed baseline. The day the
ARF injury- or failure-criteria was fulfilled according to
serum creatinine was defined as I-day 0 or F-day 0. Serum
creatinine and cystatin C were analyzed on the two days
prior to I-day 0 or F-day 0, respectively (I-day −2 and
−1, or R-day −2 and −1). Patients who did not develop
ARF served as controls. In controls, serum creatinine and
serum cystatin C were analyzed from the serum of five to
six consecutive days starting from enrollment.
Serum T3, T4, fT4, TSH, and cortisol were measured
from samples of R-day −3. Low T3- or T3/T4 syndrome
was defined as decreased T3, T4, and fT4 concentra-
tions in the reference range, or decreased and decreased
TSH values. Corticosteroid insufficiency and excess of
critically ill were defined by serum cortisol concentra-
tions <414 and >1406 nmol/L, respectively [36]. The lat-
ter cut-off value was derived from the 95th percentile
of serum cortisol in ICU patients from several studies
[37–43]. The study protocol was approved by the local
institutional review board, and it is in accordance with
the Helsinki Declaration of 1975 as revised in 1996. In-
formed consent was obtained from all patients prior to
enrollment.
Statistical analysis
The primary end point was the day ARF was detected
by serum creatinine according to the risk-criteria of the
RIFLE classification, or the respective increase of serum
cystatin C. Prior to the study, an analysis was performed
to estimate the necessary patient number in each group
required to detect a between-group difference of one SD
or less, with a 90% power and an a error less than 0.05
[14]. Based on the biological variability of serum creati-
nine and serum cystatin C described in previous studies,
a minimum of 35 patients was calculated for each group
[25, 44, 45].
Secondary end points were the days ARF was detected
by serum creatinine according to the injury- and failure-
criteria, or the respective increases of serum cystatin C.
Furthermore, we evaluated whether the etiology of ARF
or urine volumes <0.5 mL/kg/hour for six hours (risk-
criteria in the urine output domain of the RIFLE classi-
fication [35]) would affect the value of a ≥50% increase
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Table 1. Characteristics of patients
ARF Control
N 44 41
Age years 70 ± 8 63 ± 11
Female/Male N 15/29 16/25
Primary diagnosis N
Acute leukemia/lymphoma 3 (7%) 5 (12%)
Cardiovascular disease 19 (43%) 22 (53%)
Hepatic failure 7 (16%) 6 (15%)
Respiratory failure 5 (11%) 2 (5%)
Sepsis 7 (16%) 4 (10%)
Shock 2 (5%) 0 (0%)
Others 1 (2%) 2 (5%)
Etiology of ARF N
Ischemia—prerenal 5 (11%) n.a.
Nephrotoxic 4 (9%) n.a.
Sepsis 8 (18%) n.a.
Combination 27 (62%) n.a.
ARF is acute renal failure. Values are partially expressed as mean ± SD.
of cystatin C to detect ARF. Finally, we studied the ef-
fect of low T3- or T3/T4 syndrome, cortisol deficiency,
and excess on the diagnostic value of cystatin C to detect
ARF by cystatin C, and the value of cystatin C increased
by ≥50% to predict renal replacement therapy (RRT)
in the further course of ARF. Data are presented as
mean and standard deviation unless otherwise indicated.
Values are expressed either as absolute values or as per-
cent of the values from R-day −3. After testing for normal
distribution, continuous data were compared either with
the Student t test or the Mann-Whitney rank-sum test,
analysis of variance (ANOVA), or ANOVA on ranks, fol-
lowed by the Student-Newman–Keuls or Dunn’s multiple
comparison procedure. Categorical data were compared
by two-tailed Fisher exact or Chi-square test. P < 0.05
was considered to be statistically significant. Nonpara-
metric receiver operating characteristics (ROC) curves
of sensitivity and specificity with the respective areas
under the curve (AUC) for cystatin C were generated.
Sensitivity and specificity were calculated according to
the definitions of the R-, I-, and F-criteria of ARF, with
the respective cut-off values described above.
RESULTS
Of the 85 patients studied, 44 patients developed ARF
according to the R-criteria, detected by an increase of
serum creatinine ≥50%. In 41 patients (93%), ARF pro-
gressed to the I-criteria (increase of creatinine ≥100%)
1.2 ± 0.9 days after fulfilling the R-criteria. Furthermore,
in 28 patients (64%), ARF progressed to the F-criteria
(increase of creatinine ≥200%) 0.9 ± 0.4 days after reach-
ing the I-criteria. In the further course of ARF, 17 patients
(38%) required RRT. Acute renal failure was caused in
the majority of patients by a combination of the eti-
ologies ischemia, prerenal, nephrotoxicity, and sepsis.
Table 2. Risk-criteria of the RIFLE classification: Serum cystatin C
and creatinine on the three days prior to (R-day –3 to R-day −1) and
on the day ARF was detected by creatinine (R-day 0) in ARF patients
and controls
R-Day −3 R-Day −2 R-Day −1 R-Day 0
ARF
Cystatin C mg/L (%)
0.81 ± 0.13 1.13 ± 0.26b 1.45 ± 0.32b 1.79 ± 0.36b
100 142 ± 30b 182 ± 39b 226 ± 51b
Creatinine lmol/L (%)
74 ± 12 80 ± 15 90 ± 11a 139 ± 18a
100 107 ± 14 121 ± 12a 189 ± 34a
Control
Cystatin C mg/L (%)
0.88 ± 0.19 0.93 ± 0.24 0.95 ± 0.32 0.96 ± 0.27
100 106 ± 18 107 ± 19 109 ± 19
Creatinine lmol/L (%)
80 ± 13 81 ± 16 80 ± 15 79 ± 17
100 103 ± 14 102 ± 15 101 ± 18
ARF is acute renal failure. Values are expressed as mean ± SD. Percent of the
values from R-day −3 are additionally presented.
aP < 0.05 by one-way ANOVA with Student-Newman–Keuls multiple
comparison procedure.
bP < 0.05 by one-way ANOVA on ranks with Dunn’s multiple comparison
procedure.
The other 41 patients without ARF served as controls.
Patient characteristics did not differ between both groups,
as demonstrated in Table 1.
Serum creatinine and cystatin C were within the ref-
erence ranges for controls as well as ARF patients three
days before ARF was detected by an increased creati-
nine according to the R-criteria (R-day −3) (Table 2).
The ARF patients and the controls did not statistically
differ in respect to serum creatinine and cystatin C on
R-day −3. In ARF, serum creatinine increased slightly
on R-day −2 and R-day −1 (Table 2). Although this rise
was statistically significant on R-day −1, it was markedly
smaller than 50%, and the absolute creatinine values re-
mained predominantly within the reference range. On
R-day 0, serum creatinine had significantly increased, and
by definition, the percent values had risen by ≥50% com-
pared to R-day −3. In ARF, serum cystatin C and the
respective percent values rose more rapidly compared
to creatinine and had already increased significantly on
R-day −2. The mean percent increase of cystatin C
reached approximately 50% on R-day −2. On R-day −1
and R-day 0, a substantial further rise of serum cystatin C
and its percent values was observed. Thus, serum cystatin
C detected ARF 1.5 ± 0.6 days earlier than serum creati-
nine according to the R-criteria (P < 0.001). As demon-
strated in Tables 3 and 4, percent values of serum cystatin
C were also higher than serum creatinine two days prior
to ARF detection by serum creatinine, according to the
I- and F-criteria. Furthermore, serum cystatin C exhibited
a faster rise in ARF patients than creatinine. The per-
cent values reached the I- and F-criteria on I-day –1 and
F-day –1, respectively (Tables 3 and 4). Serum cystatin C
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Table 3. Injury-criteria of the RIFLE classification: Serum cystatin C
and creatinine on the two days prior to (I-day –2 and I-day −1) and on
the day ARF was detected by creatinine (I-day 0) in ARF patients
and controls
I-Day –2 I-Day −1 I-Day 0
ARF
Cystatin C mg/L (%)
1.43 ± 0.42 1.74 ± 0.50a 2.17 ± 0.61a
180 ± 47 219 ± 56a 272 ± 81a
Creatinine lmol/L (%)
87 ± 24 119 ± 27b 167 ± 34b
119 ± 21 167 ± 24b 245 ± 39b
Control
Cystatin C mg/L (%)
0.92 ± 0.23 0.90 ± 0.20 0.92 ± 0.19
108 ± 23 107 ± 24 109 ± 26
Creatinine lmol/L (%)
83 ± 15 84 ± 17 80 ± 17
102 ± 25 107 ± 22 102 ± 24
ARF is acute renal failure. Values are expressed as mean ± SD. Percent of the
values from R-day −3 are additionally presented.
a,bP < 0.05 by one-way ANOVA on ranks with Dunn’s multiple comparison
procedure.
Table 4. Failure-criteria of the RIFLE classification: Serum cystatin
C and creatinine on the two days prior to (F-day –2 and F-day −1) and
on the day ARF was detected by creatinine (F-day 0) in ARF patients
and controls
F-Day –2 F-Day –1 F-Day 0
ARF
Cystatin C mg/L (%)
1.90 ± 0.58 2.53 ± 0.55b 2.86 ± 0.75b
244 ± 69 327 ± 70b 344 ± 92b
Creatinine lmol/L (%)
101 ± 27 164 ± 31a 228 ± 32a
147 ± 30 240 ± 37a 337 ± 24a
Control
Cystatin C mg/L (%)
0.89 ± 0.21 0.88 ± 0.19 0.91 ± 0.22
105 ± 24 104 ± 21 108 ± 28
Creatinine lmol/L (%)
80 ± 16 82 ± 17 81 ± 15
99 ± 28 106 ± 27 104 ± 23
ARF is acute renal failure. Values are expressed as mean ± SD. Percent of the
values from R-day −3 are additionally presented.
aP < 0.05 by one-way ANOVA with Student-Newman–Keuls multiple
comparison procedure.
bP < 0.05 by one-way ANOVA on ranks with Dunn’s multiple comparison
procedure.
had increased by ≥100% 1.2 ± 0.9 days, and by ≥200%
1.0 ± 0.6 days prior to serum creatinine. Controls did not
demonstrate any significant changes in serum creatinine
or cystatin C during the entire study period (Tables 2
to 4).
The ROC curves, evaluating the value of serum cystatin
C to detect ARF according to an increase ≥50%, showed
that this marker performed overall well from R-day –2
to R-day 0. Areas under the curve were 0.82 [95% con-
fidence interval (CI) 0.71–0.92] for R-day −2, 0.97 (95%
CI 0.94–0.99) for R-day −1, and 0.99 (95% CI 0.98–1.00)
for R-day 0 (Fig. 1A). Applying the cut-off value of an
increase ≥50%, cystatin C had a moderate sensitivity and
a good positive predictive value on R-day −2, which both
improved considerably on R-day –1 and were excellent
on R-day 0 (Table 5). As demonstrated by ROC curves,
serum cystatin C had a good diagnostic performance to
detect ARF by an increase ≥100% on I-day –2 with an
AUC of 0.92 (95% CI 0.85–0.96). The diagnostic perfor-
mance of cystatin C increased markedly with AUCs of
0.98 (95% CI 0.94–0.99) on I-day –1, and 0.98 (95% CI
0.95–0.99) on I-day 0 (Fig. 1B). Sensitivity of cystatin C
to detect ARF by to an increase ≥100% was low on I-day
–2, but increased substantially on I-day –1 and I-day 0
(Table 5). Positive predictive values were excellent for
I-day –2 to I-day 0. Cystatin C performed excellently de-
tecting ARF according to an increase ≥200% on F-day –2
with an AUC from the respective ROC plot of 0.97 (95%
CI 0.93–0.99) (Fig. 1C). This further improved on F-day
–1 and F-day 0 with AUCs of 0.99 (95% CI 0.99–1.00) and
0.99 (95% CI 0.98–1.00), respectively. In keeping with the
results from ROC analysis, cystatin C showed low sensi-
tivity to predict ARF according to an increase ≥200%
on F-day –2 (Table 5). However, sensitivity increased on
F-day –1 and F-day 0. Positive predictive values were ex-
cellent for F-day –2 and F-day−1, and moderate for F-day
0. Applying the cut-off of an increase ≥50%, ≥100%, and
≥200%, specificity approached 100% for cystatin C on all
days studied.
Testing the predictive value of a serum cystatin C in-
crease ≥50% for the requirement of RRT in the further
course of ARF as another important end point provided
a sensitivity of 53% (95% CI 31–74) and specificity of
82% (95% CI 70–89) on R-day −2, a sensitivity of 76%
(95% CI 53–90) and specificity of 93% (95% CI 84–93)
on R-day −1, and a sensitivity of 82% (95% CI 59–94)
and specificity of 93% (95% CI 84–97) on R-day 0. Posi-
tive predictive value was low on R-day −2 [45% (95% CI
26–66)], and improved for R-day –1 and R-day 0 [76%
(95% CI 53–90, and 78% (95% CI 55–91), respectively].
Negative predictive values for a serum cystatin C increase
≥50% to predict the requirement of RRT were good to
excellent with 86% (95% CI 75–93) on R-day −2, 93%
(95% CI 84–97) on R-day −1, and 95% (95% CI 86–
98) on R-day 0. The value of a serum cystatin C increase
≥50% to predict the requirement of RRT was moder-
ate to good with AUCs of the respective ROC plots of
0.69 (95% CI 0.51–0.84) for R-day −2, 0.75 (95% CI
0.62–0.85) for R-day −1, and 0.76 (95% CI 0.69–0.85) for
R-day 0.
There was no significant association between the de-
tection of ARF according to a rise of serum cystatin
C by ≥50% and the etiologies of ARF (P = 0.38).
In ARF patients, urine volume remained stable from
R-day −3 (1.56 ± 0.48 mL/kg/hour) to R-day –1 (1.44 ±
0.65 mL/kg/hour). A moderate decrease of urine
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volume was noticed on R-day 0 (1.23 ± 0.81 mL/kg/hour)
(P = 0.24). Two ARF patients developed urine volumes
<0.5 mL/kg/hour on R-day –1 another four ARF patients
on R-day 0, thus also fulfilling the R-criteria of the urine
output domain of the RIFLE classification [35]. In the
other 38 ARF patients, urine volume on R-day 0 did not
differ from R-day –3 (1.43 ± 0.66 mL/kg/hour). In the
six patients with reduced urine volume, serum cystatin
C detected ARF 1.5 ± 0.5 days prior to the decrease in
urine volume. In controls, urine volumes remained sta-
ble and did not differ from those of ARF patients on
R-day −3.
ARF and control patients did not markedly differ in
respect to T3, T4, fT4, TSH, and cortisol values (Table 6).
Seventeen ARF patients (39%) presented with low T3-
or T3/T4 syndrome compared to 13 controls (32%) (P =
0.65). Ten ARF (23%) and nine control patients (20%)
had serum cortisol <414 nmol/L (P = 0.86). Serum cor-
tisol concentrations were >1304 nmol/L in 3 ARF (7%)
and 4 control patients (10%) (P = 0.71). From R-day −2
to R-day 0, serum cystatin C was not significantly differ-
ent in ARF and control patients with or without low T3-
or T3/T4 syndrome. Similarly, cystatin C values did not
significantly differ either in ARF or control patients with
serum cortisol < or ≥414 nmol/L, and ≤ or >1406 nmol/L
on R-day −2 to R-day 0.
DISCUSSION
Our results indicate that serum cystatin C performs
well as a marker to detect ARF. In addition, cystatin C
may permit to detect the development of ARF one to two
days earlier than serum creatinine, the current standard
marker for ARF. We found that cystatin C detected ARF
earlier according to a more sensitive (increase≥50%) and
to more specific definitions (increase ≥100% or ≥200%),
which are analogous to the R-, I-, and F-criteria of the
recently proposed RIFLE classification [35]. As a fur-
ther major finding, a serum cystatin C increase ≥50%
was demonstrated to predict the RRT requirement in
the course of ARF moderately well. Thus, serum cystatin
C may be a valid marker in the early and later stages
of ARF. Our findings are of clinical importance because
early detection of ARF can provide time to prevent the
progression of ARF [8–10]. Early initiation of preven-
tive measures may improve the outcome in ARF, a con-
dition that substantially increases mortality [3, 5, 6, 7].
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 1. ROC plots demonstrating the performance of serum cystatin C
to detect ARF by an increase ≥50% (A), ≥100% (B), and ≥200% (C).
The ROC curves of the two days prior to ARF and of the day ARF was
detected by serum creatinine according to the R-, I-, and F-criteria, are
presented: R-day −2 to R-day 0 (A), I-day −2 to I-day 0 (B), and F-day
−2 to F-day 0 (C).
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Table 5. Diagnostic performance of serum cystatin C detecting ARF by an increase ≥50%, ≥100%, and ≥200% two days and one day (day −2
and −1) prior and on the day (day 0) ARF was detected by serum creatinine according to the risk (R)-, injury (I)-, and failure (F)-criteria of RIFLE
R-Day −2 R-Day −1 R-Day 0
Risk criteria
ARF patients fulfilling criteria N 24 36 42
Sensitivity 55% (45–64) 82% (73–88) 98% (93–99)
Specificity 95% (89–98) 95% (89–98) 93% (86–97)
PPV 92% (76–98) 95% (83–99) 93% (82–98)
NPV 66% (53–77) 83% (70–91) 95% (84–99)
I-Day –2 I-Day −1 I-Day 0
Injury criteria
ARF patients fulfilling criteria N 16 31 38
Sensitivity 39% (29–49) 76% (66–84) 93% (85–97)
Specificity 100% (96–100) 100% (96–100) 96% (90–99)
PPV 100% (81–100) 100% (89–100) 95% (84–99)
NPV 63% (51–74) 81% (69–89) 93% (82–98)
F-Day −2 F-Day −1 F-Day 0
Failure criteria
ARF patients fulfilling criteria N 11 24 27
Sensitivity 40% (30–51) 85% (76–91) 96% (90–99)
Specificity 100% (96–100) 100% (96–100) 92% (84–96)
PPV 100% (74–100) 100% (86–100) 87% (71–95)
NPV 76% (65–84) 93% (83–97) 98% (90–100)
PPV, positive predictive value; NPV, negative predictive value. 95% CIs are given in parentheses.
Table 6. Serum concentrations of thyroid hormones, TSH, and
cortisol in ARF and control patients three days prior to the detection
of ARF by creatinine according to the risk-criteria
Range ARF Control P value
T3 nmol/L 1.2–3.1 1.2 ± 0.6 1.3 ± 0.4 0.18a
T4 nmol/L 58–154 74 ± 31 65 ± 32 0.19b
FT4 pmol/L 10–25 18 ± 3 14 ± 3 0.17b
TSH mU/L 0.3–3.0 1.4 ± 1.2 1.9 ± 1.1 0.10a
Cortisol nmol/L 130–690 744 ± 317 714 ± 329 0.56a
ARF is acute renal failure. Values are expressed as mean ± SD.
aTesting was done using the Mann-Whitney rank-sum.
bTesting was done using Student t test.
Therefore, serum cystatin C could aid to advance the RI-
FLE classification after external validation of our results.
Cystatin C has been identified as a superior GFR
marker to creatinine in chronic renal insufficiency with
small variability [13, 15, 16, 19–22, 44, 45]. Serum cystatin
C measurement is highly accurate and precise [15, 44,
46]. The commercially available immunonephelometric
assay provides rapid, automated measurement of cystatin
C and requires few minutes until results are available [16,
46]. Additionally, preanalytic factors such as routine clin-
ical storage conditions, freezing and thawing cycles, or
interfering substances, such as bilirubin or triglycerides,
do not affect cystatin C measurement [44, 46].
The few published longitudinal studies on cystatin C
predominantly support our finding that serum cystatin C
reflects GFR changes more rapidly compared to serum
creatinine [23, 25, 26]. One explanation may be that cys-
tatin C, unlike creatinine, resembles more closely an ideal
endogenous marker of glomerular filtration [17, 18], ex-
cept for a few, negligible exceptions [27, 28, 32–34]. This
is in contrast to the numerous nonrenal factors that in-
fluence the generation of creatinine, its tubular secretion,
and backleak, which may result in inaccurate reflection
of GFR by creatinine [12]. Another potential explanation
emerges from recent observations that cystatin C and cre-
atinine differ in regard to their glomerular filtration char-
acteristics during pregnancy and diabetic nephropathy
[47, 48]. It remains speculative whether this phenomenon
occurs also in ARF, but alterations in glomerular pore
size could cause differences in the glomerular filtration
of cystatin C and creatinine during ARF. However, there
are conflicting data, although of smaller patient popula-
tions, which demonstrate a more rapid rise of serum crea-
tinine compared to cystatin C in acute renal graft rejection
[22, 24].
Besides ARF, no other factor was identified to modify
serum cystatin C levels, which enhances its usefulness as
detection marker of ARF. Neither the etiology of ARF
nor urine volume demonstrated any effect on the predic-
tive value of serum cystatin C in ARF.
Low T3- or T3/T4 syndrome, glucocorticoid deficiency,
or excess did not markedly affect serum cystatin C, ex-
cluding these factors as nonrenal confounders of serum
cystatin C in ARF. This is crucial because these en-
docrine disorders may frequently occur in critically ill
ARF patients. However, serum cortisol levels vary widely
in critically ill patients, and no upper reference value has
been defined yet. Thus, we derive the cut-off value of
>1406 nmol/L for serum cortisol from various studies to
analyze the potential effect of glucocorticoid excess on
serum cystatin C in ARF [37–43]. In addition, we realize
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that the diagnosis of glucocorticoid deficiency in our study
was based on one random morning measurement without
performing a corticotropin stimulation test, a procedure
that is not unchallenged [36, 38]. Due to exclusion of the
respective patients, our results may not be valid for pa-
tients on thyroid or high-dose glucocorticoid therapy, pa-
tients with aortic aneurysms, hyper- or hypothyroidism.
Glucocorticoids were demonstrated to increase the
transcription of the cystatin C gene, and thyroid hor-
mones appear to have an increasing effect on cystatin
C [30, 32, 49]. In contrast, hypothyroidism and aortic
aneurysms are associated with low serum cystatin C levels
[32–34].
Focusing on patients with initially normal serum cre-
atinine values limits this study. However, these patients
especially may profit more from early detection of ARF
because they are generally given less attention in regard
to ARF and may develop ARF unnoticed compared to
those with already increased creatinine values at baseline.
Yet, our findings may not apply to patients with acute on
chronic renal failure. Additionally, our cohort may not be
entirely representative for ARF, and our findings may not
be valid for patients who develop ARF together with the
associated increase of GFR markers more rapidly. Fur-
thermore, our study was performed at three ICUs of one
hospital, which may have made it vulnerable to a center
effect. These results certainly require independent valida-
tion on a larger patient size. Because we did not measure
GFR, we cannot and did not intend to comment whether
serum cystatin C or creatinine correlate more accurately
with decreases of GFR in ARF. In spite of this limitation,
estimates of GFR as serum creatinine and cystatin C are
considered to be acceptable markers to detect ARF in
clinical settings [3–6, 11–14, 35].
CONCLUSION
Our results suggest that serum cystatin C is a useful de-
tection marker in ARF, and superior to serum creatinine.
Cystatin C may detect ARF one to two days earlier than
creatinine. Early detection may provide time to prevent
the progression of ARF and improve its negative impact
on outcome.
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